A Study of YL201 in Patients With Advanced Solid Tumors

2024-517589-41-00 Protocol YL201-INT-101-01 Human pharmacology (Phase I) - First administration to humans Authorised, recruiting

Start 4 Aug 2025 · Status Authorised, recruiting · 3 EU/EEA countries · 20 sites · Protocol YL201-INT-101-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruiting
Participants planned 261
Countries 3
Sites 20

Advanced solid tumors

Key facts

Sponsor
Medilink Therapeutics (Suzhou) Co. Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
4 Aug 2025 → ongoing
Decision date (initial)
2025-07-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517589-41-00
ClinicalTrials.gov
NCT05434234

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

VersionLevelCodeTermSystem organ class
21.0 LLT 10048683 Advanced cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Medilink Therapeutics (Suzhou) Co. Ltd.

Sponsor organisation
Medilink Therapeutics (Suzhou) Co. Ltd.
Address
B3-101 Biobay 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Pilot Free Trade Zone Suzhou Industrial Park Jiangsu Pilot Free Trade Zone
City
Suzhou
Postcode
215123
Country
China

Scientific contact point

Organisation
Medilink Therapeutics (Suzhou) Co. Ltd.
Contact name
Medilink Therapeutics

Public contact point

Organisation
Medilink Therapeutics (Suzhou) Co. Ltd.
Contact name
Medilink Therapeutics

Locations

3 EU/EEA countries · 20 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruiting 28 8
Poland Authorised, recruiting 17 1
Spain Authorised, recruiting 70 11
Rest of world
United States, Canada, China
146

Investigational sites

France

8 sites · Authorised, recruiting
Centre Hospitalier Universitaire De Nantes
Departement Oncologie Medicale – Unite Oncologie Thoracique, Boulevard Du Professeur Jacques Monod, 44800, Saint Herblain
Institut De Cancerologie De L Ouest
Medical Oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Centre Hospitalier Universitaire De Bordeaux
Department of Medical Oncology, 1 Rue Jean Burguet, Cs 11261, Bordeaux Cedex
Centre Hospitalier Regional De Marseille
CEPCM-CLIPP, 264 Rue Saint Pierre, 13005, Marseille
Centre Hospitalier Universitaire De Poitiers
Medical Oncology, 2 Rue De La Miletrie, 86000, Poitiers
Institut Curie
Department of Drug Development and Innovation (D3i), 26 Rue D Ulm, 75005, Paris
Centr Georges Francois Leclerc
Medical Oncology Department, 1 Rue Professeur Marion, 21000, Dijon
Hospital Foch
Services de Pneumologie & d’Oncologie Medicale, 40 Rue Worth, 92150, Suresnes

Poland

1 site · Authorised, recruiting
Europejskie Centrum Zdrowia Otwock Sp. z o.o.
Oddzial Onkologii Klinicznej i Chemioterapii, Ul. Borowa 14/18, 05-400, Otwock

Spain

11 sites · Authorised, recruiting
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital De La Santa Creu I Sant Pau
Oncology, Calle De San Antonio Maria Claret 167, 08025, Barcelona
Hospital Universitario Severo Ochoa
Oncology, Avenida Orellana S/n, 28911, Leganes
Clinica Universidad De Navarra
Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Clinica Universidad De Navarra
Oncology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitario Ramon Y Cajal
Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-09-10
Poland 2025-09-03
Spain 2025-08-04

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-03-19 Spain Acceptable
2025-07-04
2025-07-07
2 SUBSTANTIAL MODIFICATION SM-2 2025-08-07 Acceptable 2025-08-28
3 SUBSTANTIAL MODIFICATION SM-3 2025-09-17 Spain Acceptable
2025-12-16
2025-12-18
4 SUBSTANTIAL MODIFICATION SM-4 2026-02-24 Spain Acceptable
2026-05-21
2026-05-22
5 NON SUBSTANTIAL MODIFICATION NSM-1 2026-05-28 Acceptable
2026-05-21
2026-05-28